Open an account

Mereo BioPharma Group

MREO · NASDAQ

$0.2951−$0.007 (−2.32%)TodayMarket closed ·
Prev close $0.3021

About MREO

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.

Employees
39
Headquarters
London
Listed
Jun 9, 2016
Sector
Health Care
Industry
Biotechnology
Website
mereobiopharma.com

MREO key statistics

Market cap
48.22M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.55M
Volume
494.05K
Open price
$0.3081
High today
$0.3183
Low today
$0.2942
52 Week high
$2.37
52 Week low
$0.20

Mereo BioPharma Group (MREO) at a glance

Mereo BioPharma Group (MREO) last traded at $0.2951, with a market cap of 48.22M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.2942 and $0.3183. The current price is 0.3% above the day's low and 7.3% below its high.

Volume so far is 494.05K shares, below the average of 1.55M shares a day.

Over the past year Mereo BioPharma Group has ranged from $0.20 to $2.37, and now sits 4% of the way up that range.

Mereo BioPharma Group met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.01 per share against an estimate of -$0.0082.

The average analyst price target is $1.78, 504.9% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

40%of 5 analyst ratings say Buy
  • Buy40.0%
  • Hold40.0%
  • Sell20.0%
Price target · 8 analystsAvg $1.78
Low
$0.505
Now
$0.2951
High
$3.15

MREO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 28.4% on average.

  1. Q3 FY24: reported -$0.10 per share against an estimate of -$0.0179
  2. Q4 FY24: reported -$0.05 per share against an estimate of -$0.0147
  3. Q1 FY25: reported -$0.10 per share against an estimate of -$0.0074
  4. Q2 FY25: reported -$0.10 per share against an estimate of -$0.0167
  5. Q3 FY25: reported -$0.01 per share against an estimate of -$0.0248
  6. Q4 FY25: reported -$0.01 per share against an estimate of -$0.0131
  7. Q1 FY26: reported -$0.01 per share against an estimate of -$0.0102
  8. Q2 FY26: reported -$0.01 per share against an estimate of -$0.0082

MREO news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releasePRNewswire

    Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

  • Press releaseGlobe Newswire

    Class Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join – Contact Levi & Korsinsky

  • Press releaseGlobe Newswire

    MEREO LAWSUIT DEADLINE TODAY: Bragar Eagel & Squire, P.C. Urges Mereo BioPharma Stockholders with Large Losses to Contact the Firm Regarding Their Rights

  • Press releaseBusiness Wire

    MREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026

  • Press releasePRNewswire

    Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Similar companies

Companies in the same industry as Mereo BioPharma Group

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.